肝硬化伴肌少症患者运动干预的最佳证据总结

doi:10.3761/j.issn.1672-9234.2023.12.015

摘要/Abstract

摘要：

目的检索、评价并总结肝硬化伴肌少症患者运动干预的最佳证据，为医疗保健人员提供参考。方法计算机检索UpToDate、BMJ、JBI、Cochrane Library、Web of Science、PubMed、Embase、中国知网、万方数据、维普、中国生物医学文献服务系统等数据库中关于肝硬化伴肌少症患者运动干预的文献，检索时限为建库至2023年5月2日。结果共纳入10篇文献，包括2篇指南、2篇专家共识、6篇系统评价。最终总结出肝硬化伴肌少症患者包括运动前评估、运动方式、运动强度、运动频率与时间、运动监测、质量控制共6个方面21条最佳证据。结论本研究总结了肝硬化伴肌少症患者进行运动干预的最佳证据，建议医疗保健人员对患者进行运动前评估，选择个体化的运动方式、强度、频率和时间，动态监测患者的病情进展、肌肉力量、质量、身体机能等相关指标，从而确保运动干预的安全性与有效性，提升患者的活动耐力与生活质量。

关键词: 肝硬化, 循证护理学, 运动疗法, 肌少症, 证据总结

Abstract:

Objective To search，evaluate and summarize the best evidence for exercise intervention in patients with liver cirrhosis and sarcopenia，and to provide reference for health care personnel. Methods To retrieve the literature on exercise intervention in patients with cirrhosis and sarcopenia，a computer-based search was undertaken in databases including UpToDate，BMJ，JBI，Cochrane Library，Web of Science，PubMed，Embase，CNKI，Wanfang Data，VIP，CBM and other databases. The search time limit was set from the establishment of the databases to May 2，2023. Results A total of 10 articles were included，including two guidelines，two expert consensus，and six systematic reviews. Finally，21 best evidences in six aspects including pre-exercise evaluation，exercise mode，exercise intensity，exercise frequency and time，exercise monitoring and quality control were summarized for patients with cirrhosis and sarcopenia. Conclusion This study summarized the best evidence for exercise intervention in patients with liver cirrhosis and sarcopenia. It is recommended that health care personnel should evaluate patients before exercise，select individualized exercise methods，intensity，frequency and time，and dynamically monitor the patients’ disease progression，muscle strength，quality，body function and other related indicators to ensure the safety and effectiveness of exercise intervention and improve the patients’ activity endurance as well as quality of life.

Key words: Liver Cirrhosis, Exercise Therapy, Evidence-Based Nursing, Sarcopenia, Evidence summary

田甘露, 何文英, 陈泽阳. 肝硬化伴肌少症患者运动干预的最佳证据总结[J]. 中华护理教育, 2023, 20(12): 1493-1499.

TIAN Ganlu, HE Wenying, CHEN Zeyang. Best evidence summary of exercise intervention in patients with liver cirrhosis and sarcopenia[J]. Chinese Journal of Nursing Education, 2023, 20(12): 1493-1499.

图/表 4

参考文献 28

[1]	aumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in new Mexico[J]. Am J Epidemiol, 1998, 147(8):755-763. doi: 10.1093/oxfordjournals.aje.a009520 pmid: 9554417
[2]	Kim G, Kang SH, Kim MY, et al. Prognostic value of sarco-penia in patients with liver cirrhosis:a systematic review and meta-analysis[J]. PLoS One, 2017, 12(10):e0186990. doi: 10.1371/journal.pone.0186990
[3]	Tantai XX, Liu Y, Yeo YH, et al. Effect of sarcopenia on survival in patients with cirrhosis:a meta-analysis[J]. J Hepatol, 2022, 76(3):588-599. doi: 10.1016/j.jhep.2021.11.006
[4]	Van Vugt J, Buettner S, Alferink L, et al. SUN-P072:low skele-tal muscle mass is associated with increased hospital costs in patients with cirrhosis listed for liver transplantation[J]. Clin Nutr, 2017, 36:S80.
[5]	伍静薇, 张莉, 杨平. 肝硬化伴肌少症病人运动干预研究进展[J]. 护理研究, 2020, 34(23):4221-4225.
	Wu JW, Zhang L, Yang P. Research progress of exercise intervention in patients with liver cirrhosis and sarcopenia[J]. Chin Nurs Res, 2020, 34(23):4221-4225.
[6]	Dicenso A, Bayley L, Haynes RB. Accessing pre-appraised evi-dence:fine-tuning the 5S model into a 6S model[J]. Evid Based Nurs, 2009, 12(4):99-101. doi: 10.1136/ebn.12.4.99-b pmid: 19779069
[7]	Brouwers MC, Kerkvliet K, Spithoff K, et al. The AGREE Repor-ting Checklist:a tool to improve reporting of clinical practice guidelines[J]. BMJ, 2016, 352:i1152.
[8]	陈尹, 胡世莲, 李幼平, 等. 全球药物干预治疗单纯性高血压指南的系统评价[J]. 中国循证医学杂志, 2012, 12(10):1180-1194.
[9]	顾莺, 张慧文, 周英凤, 等. JBI循证卫生保健中心关于不同类型研究的质量评价工具:系统评价的方法学质量评价[J]. 护士进修杂志, 2018, 33(8):701-703.
[10]	顾莺, 张慧文, 周英凤, 等. JBI循证卫生保健中心关于不同类型研究的质量评价工具:分析性研究的质量评价[J]. 护士进修杂志, 2018, 33(5):400-403.
[11]	王春青, 胡雁. JBI证据预分级及证据推荐级别系统(2014版)[J]. 护士进修杂志, 2015, 30(11):964-967.
[12]	Lai JC, Tandon P, Bernal W, et al. Malnutrition,frailty,and sarcopenia in patients with cirrhosis:2021 practice guidance by the American association for the study of liver diseases[J]. Hepatology, 2021, 74(3):1611-1644. doi: 10.1002/hep.32049
[13]	Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clini-cal practice guidelines for Liver Cirrhosis 2020[J]. J Gas-troenterol, 2021, 56(7):593-619.
[14]	Carey EJ, Lai JC, Sonnenday C, et al. A North American expert opinion statement on sarcopenia in liver transplantation[J]. Hepatology, 2019, 70(5):1816-1829. doi: 10.1002/hep.30828 pmid: 31220351
[15]	Kamada Y, Takahashi H, Shimizu M, et al. Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan:an expert review[J]. J Gastroenterol, 2021, 56(12):1045-1061. doi: 10.1007/s00535-021-01833-9
[16]	Aamann L, Dam G, Rinnov A, et al. Physical exercise for people with cirrhosis[J]. Cochrane Database Syst Rev, 2018, 12(12):CD012678.
[17]	Naseer M, Turse EP, Syed A, et al. Interventions to improve sarcopenia in cirrhosis:a systematic review[J]. World J Clin Cases, 2019, 7(2):156-170. doi: 10.12998/wjcc.v7.i2.156
[18]	Brustia R, Savier E, Scatton O. Physical exercise in cirrhotic pa-tients:towards prehabilitation on waiting list for liver trans-plantation. A systematic review and meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2018, 42(3):205-215. doi: 10.1016/j.clinre.2017.09.005
[19]	Gonzalez A, Valero-Breton M, Huerta-Salgado C, et al. Impact of exercise training on the sarcopenia criteria in non-alcoholic fatty liver disease:a systematic review and meta-analysis[J]. Eur J Transl Myol, 2021, 31(1):9630.
[20]	Johnston HE, Takefala TG, Kelly JT, et al. The effect of diet and exercise interventions on body composition in liver cirrhosis:a systematic review[J]. Nutrients, 2022, 14(16):3365. doi: 10.3390/nu14163365
[21]	Jamali T, Raasikh T, Bustamante G, et al. Outcomes of exer-cise interventions in patients with advanced liver disease:a systematic review of randomized clinical trials[J]. Am J Gas-troenterol, 2022, 117(10):1614-1620.
[22]	Duarte-Rojo A, Ruiz-Margáin A, Montaño-Loza AJ, et al. Exer-cise and physical activity for patients with end-stage liver disease:improving functional status and sarcopenia while on the transplant waiting list[J]. Liver Transpl, 2018, 24(1):122-139. doi: 10.1002/lt.24958
[23]	Faustini Pereira JL, Galant LH, Rossi D, et al. Functional ca-pacity,respiratory muscle strength,and oxygen consumption predict mortality in patients with cirrhosis[J]. Can J Gastroe-nterol Hepatol, 2016, 2016:6940374.
[24]	Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resista-nce exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss[J]. Gut, 2011, 60(9):1278-1283. doi: 10.1136/gut.2011.242073 pmid: 21708823
[25]	Francaux M, Deldicque L. Exercise and the control of muscle mass in human[J]. Pflugers Arch, 2019, 471(3):397-411. doi: 10.1007/s00424-018-2217-x
[26]	Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease:a systematic review[J]. J Hepatol, 2017, 66(1):142-152. doi: S0168-8278(16)30488-3 pmid: 27639843
[27]	Whitsett M, VanWagner LB. Physical activity as a treatment of non-alcoholic fatty liver disease:a systematic review[J]. World J Hepatol, 2015, 7(16):2041-2052. doi: 10.4254/wjh.v7.i16.2041 pmid: 26261693
[28]	Iwanaga S, Hashida R, Takano Y, et al. Hybrid training system improves insulin resistance in patients with nonalcoholic fatty liver disease:a randomized controlled pilot study[J]. Tohoku J Exp Med, 2020, 252(1):23-32. doi: 10.1620/tjem.252.23 pmid: 32863329